NCT01084187

Brief Summary

The purpose of the study is to assess the correlation of FMD of brachial artery and carotid intima media thickness with ED severity and clinical response to vardenafil in hypertensive men.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 10, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
Last Updated

April 18, 2011

Status Verified

April 1, 2011

Enrollment Period

11 months

First QC Date

March 9, 2010

Last Update Submit

April 15, 2011

Conditions

Keywords

erectile dysfunctionarterial hypertensionflow mediated vasodilationendothelial dysfunctioncarotid intima media thicknessvardenafil

Outcome Measures

Primary Outcomes (1)

  • clinical response to vardenafil

    SEP 2; SEP 3 and IIEF variation

    four weeks

Secondary Outcomes (1)

  • endothelial dysfunction

    four weeks

Study Arms (3)

vardenafil on demand

ACTIVE COMPARATOR

four sexual attempts with 20 mg vardenafil during next four weeks

Drug: Vardenafil

placebo

PLACEBO COMPARATOR

placebo of vardenafil during four weeks

Drug: Vardenafil

daily vardenafil

ACTIVE COMPARATOR

10 mg of vardenafil each day during four weeks

Drug: Vardenafil

Interventions

vardenafil 20 mg on demand or vardenafil daily or placebo

Also known as: Levitra
daily vardenafilplacebovardenafil on demand

Eligibility Criteria

Age50 Years - 70 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • arterial hypertension and erectile dysfunction of vascular origin for at least 6 month

You may not qualify if:

  • other condition that cause erectile dysfunction such as depression, hypogonadism, surgery, trauma, major cardiovascular event

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitário Pedro Ernesto

Rio de Janeiro, Rio de Janeiro, 20551030, Brazil

Location

MeSH Terms

Conditions

Erectile DysfunctionHypertension

Interventions

Vardenafil Dihydrochloride

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental DisordersVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperazines

Study Officials

  • Mario F Neves, MD, PhD.

    Hospital Universitario Pedro Ernesto

    STUDY CHAIR
  • Valter Javaroni, MD, MSc

    State University of Rio de Janeiro

    PRINCIPAL INVESTIGATOR
  • Wille Oigman, MD, PhD

    State University of Rio de Janeiro

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 9, 2010

First Posted

March 10, 2010

Study Start

January 1, 2010

Primary Completion

December 1, 2010

Study Completion

February 1, 2011

Last Updated

April 18, 2011

Record last verified: 2011-04

Locations